Indications & Uses
Triamace is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Adults: This cream should be applied sparingly to the skin lesion no more than 2 times daily, preferably once in the morning and once in the evening. This cream should not be applied with an occlusive dressing, or to large areas of skin on the body. The duration of treatment with this cream should continue until the inflammatory symptoms subside but not longer than 2 weeks; after 2 weeks of therapy with this cream, continue therapy as needed with a preparation containing econazole or econazole nitrate alone.Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight. Caution should be exercised.
Side Effects
Rarely, transient mild local irritation, itching, and redness may occur immediately after application. Econazole has minimal allergenic potential and is well tolerated, even by delicate skin. Adrenal suppression may occur with long-term continuous use of topical steroids, particularly in infants and children or when occlusive dressings are used. Note that an infant's napkin can act as an occlusive dressing.
Cautions & Contraindications
Warnings & Precautions
For external use only. This Cream is not for ophthalmic or oral use. If a reaction suggesting hypersensitivity or chemical irritation should occur, use of the medication should be discontinued. Corticosteroids applied to the skin can be absorbed in sufficient amounts to produce systemic effects, including adrenal suppression. Systemic absorption may be increased by various factors such as application over a large skin surface area, application to damaged skin, application under occlusive skin dressings and prolonged duration of therapy. Topical corticosteroids are associated with skin thinning and atrophy, striae, telangiectasis and purpura. Topical corticosteroids may lead to increased risk of dermatological superinfection or opportunistic infection. Children: Increased caution is required when treating children. Compared to adults, the nature of a child's skin and the larger skin surface area relative to body weight may lead to an increased absorption of the corticosteroid via the child's skin. This cream should be used in children only for short periods of time (less than 2 weeks) and on small areas (less than 10% of body surface area).Visual disturbance may be associated with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR).
Contraindications
Contraindicated for use in individuals with known hypersensitivity to any of its ingredients. As with other corticosteroid-containing dermatological preparations, this cream should not be used on skin affected by tuberculosis, chickenpox (varicella), herpes simplex, or other viral infections, nor applied to fresh vaccination sites. It is also contraindicated in decubitus ulcers; in viral, bacterial, or fungal skin infections such as cutaneous tuberculosis, cutaneous syphilis, herpes simplex, herpes zoster, and chickenpox; and in rosacea or rosacea-like dermatitis.